In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Start-Up Previews (06/2010)

Executive Summary

A preview of the emerging health care companies profiled in the current issue of Start-Up. "Altering The Insulin Resistance System" features profiles of Catabasis Pharmaceuticals, Limerick BioPharma, Marcadia BIotech and Rhythm Pharmaceuticals. Plus these Start-Ups Across Health Care: nContact Surgical, NormOxys and Thermopeutix.

You may also be interested in...



ThermopeutiX Inc.

Patients afflicted with acute stroke may soon have their brain protected from reduced cerebral blood flow by being induced with selective hypothermia, as opposed to being subjected to systemic cooling, which lowers the entire body's temperature, but may stop the heart in the process. ThermopeutiX Inc.'s DuoFlo is a dual-lumen catheter system that removes warm blood from the body through one lumen and delivers cold blood to the brain through a second lumen. The novel technology is designed to be used primarily by interventional cardiologists and interventional radiologists -- rather than neurologists -- to treat not only stroke, but cardiac arrest and trauma as well.

nContact Surgical Inc.

nContact Surgical Inc. aims to merge the best of surgical and interventional techniques to provide a truly minimally invasive, single procedure solution for atrial fibrillation patients. Its Numeris Coagulation system with VisiTrax is used in the surgical portion of the procedure, in which VisiTrax integrates suction, perfusion and radiofrequency energy to create long linear lesions on the outside of a beating heart. The electrophysiologist then uses a catheter to complete the biatrial lesion pattern inside the heart.

Merck Takes A New Shot At Alzheimer’s With Cerevance Deal

The major will use the biotech’s brain cell-focused platform technology to discover new targets for Alzheimer’s disease.

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV003518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel